==== Front Exp Hematol Oncol Exp Hematol Oncol Experimental Hematology & Oncology 2162-3619 BioMed Central London 194 10.1186/s40164-020-00194-y Review Applications of gut microbiota in patients with hematopoietic stem-cell transplantation http://orcid.org/0000-0003-1217-4385Yu Jifeng 12 Sun Hao 3 Cao Weijie 1 Han Lijie 1 Song Yongping 4 Wan Dingming wwddmm@vip.sina.com 1 Jiang Zhongxing jiangzx@zzu.edu.cn 1 1 grid.412633.1Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052 China 2 grid.207374.50000 0001 2189 3846Academy of Medical and Pharmaceutical Sciences of Zhengzhou University, Zhengzhou, 450052 China 3 grid.412633.1Department of Radiotherapy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052 China 4 grid.414008.90000 0004 1799 4638The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, 450008 China 4 12 2020 4 12 2020 2020 9 352 10 2020 27 11 2020 © The Author(s) 2020Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.Studies of the gut microbiota (GM) have demonstrated the close link between human wellness and intestinal commensal bacteria, which mediate development of the host immune system. The dysbiosis, a disruption of the microbiome natural balance, can cause serious health problems. Patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) may cause significant changes in GM due to their underlying malignancies and exposure to extensive chemotherapy and systemic antibiotics, which may lead to different disorders. There are complex and multi-directional interactions among intestinal inflammation, GM and immune reactivity after HSCT. There is considerable effect of the human intestinal microbiome on clinical course following HSCT. Some bacteria in the intestinal ecosystem may be potential biomarkers or therapeutic targets for preventing relapse and improving survival rate after HSCT. Microbiota can be used as predictor of mortality in allo-HSCT. Two different strategies with targeted modulation of GM, preemptive and therapeutic, have been used for preventing or treating GM dysbiosis in patients with HSCT. Preemptive strategies include enteral nutrition (EN), prebiotic, probiotic, fecal microbiota transplantation (FMT) and antibiotic strategies, while therapeutic strategies include FMT, probiotic and lactoferrine usages. In this review, we summarize the advance of therapies targeting GM in patients with HSCT. Keywords Targeted modulation therapyGut microbiotaHematopoietic stem cell transplantation (HSCT)http://dx.doi.org/10.13039/501100004609Foundation of Henan Educational Committee20A320062Yu Jifeng http://dx.doi.org/10.13039/501100011447Science and Technology Department of Henan ProvinceLHGJ20190039Yu Jifeng issue-copyright-statement© The Author(s) 2020 ==== Body Introduction Thousands of different species of micobiome are colonized at different sites of human body and play a key role in maintaining our health or promoting disease [1]. Studies of the gut microbiota (GM) have demonstrated the close link between human wellness and intestinal commensal bacteria, which mediate development of the host immune system [2]. The dysbiosis, a disruption of the microbiome natural balance, can cause serious health problems [3, 4]. Patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) may cause significant changes in GM due to their underlying malignancies and exposure to extensive chemotherapy and systemic antibiotics, which may lead to biological disorders. Studies have shown that there are complex and multi-directional interactions among intestinal inflammation, GM and immune reactivity after HSCT. There is mounting evidence for the considerable effect of the human intestinal microbiome on clinical course following HSCT [5–7]. The abundance or presence of some bacteria in the intestinal ecosystem may be potential biomarkers or therapeutic targets for preventing relapse and improving survival rate after HSCT [8]. Most recent study showed that microbiota can be used as predictor of mortality in allo-HSCT [9]. Many studies have showed that targeted modulation of GM in patients with HSCT has potential therapeutic implications [10]. In this review, we summarize the advance of therapies targeting GM in patients with HSCT. Mechanism of gut microbiota in graft versus host disease (GvHD) Gut GvHD is the result of conditioning toxicity and immune activation associated with injury of the stem-cell compartments along with Paneth and goblet cells in the intestinal mucosa [11]. This leads to increased intestinal permeability, inflammation, and reduction of the mucous membrane [12, 13]. The mucus layer produced by goblet cells acts as a physical barrier in the gut and regulates the relationship between the microbiota and the host [14]. Intestinal epithelial cells, dendritic cells, and macrophages express pattern recognition receptors, such as Toll-like receptors, which can recognize microbe-associated molecular patterns. Activation of these receptors triggers proinflammatory cytokine response and presents antigens to regulatory T cells (Tregs). Activation of Tregs conveys tolerance towards commensal bacteria [14]. Gut bacteria produce Butyrate and other short-chain fatty acid (SCFA), which exert anti-inflammatory effects on the macrophages and the dendritic cells through inhibiting histone deacetylase (HDAC), inhibiting NF-κB signaling and increasing IL-10 expression [15]. Metabolomics analysis of human acute graft-versus-host disease reveals changes in host and microbiota-derived metabolites [16]. Most recent study revealed that Butyrate was significantly decreased in all gastro-intestinal (GI) acute GvHD (aGVHD) stages. Specific microbiota and metabolic alterations were associated with aGVHD severity and may be useful for diagnostic and pathophysiologic purposes [17]. Segmented filamentous bacteria can penetrate the mucus layer and interact with epithelial cells, inducing the differentiation of T helper 17 (Th17) cells [18]. Th17 cells are specialized in responses to extracellular bacteria and fungi by secretion of cytokines such as IL-17A, IL-17F, IL-21, and IL-22 [18]. The cytokines produced by Th17 cells induce secretion of antimicrobial peptides such as the α-defensins and RegIIIγ by the Paneth cells [14]. Patients with hematological diseases requiring HSCT undergo extensive preconditioning chemotherapy as well as antibiotic or antifungal treatments. Although antibiotic treatment in HSCT patients is essential in many patients to avoid bacterial infections, these interventions result in the disruption of the gut microbiota and its equilibrium and can cause additional gastrointestinal damage. Studies have shown that there is a high risk of bacterial infection during transplantation, and subsequent GvHD and low GM diversity are closely associated with transplant related mortality [19, 20]. Alteration of the intestinal microbiota by broad-spectrum antibiotic use correlates with the occurrence of intestinal GvHD [21]. GvHD occurs in a large number of patients receiving allo-HSCT, resulting in a mortality rate of up to 30% [22]. Extensive studies of monitoring microbiome alterations have been done, especially regarding the GM and the GvHD in patients with HSCT [7–10, 23]. The most recent study showed patterns of microbiota disruption during allo-HSCT were similar across transplantation centers and geographic locations. Patterns were characterized by loss of diversity and domination by single taxa. Higher diversity of intestinal microbiota at the time of neutrophil engraftment was associated with lower mortality [9]. The microbiota can be used as predictor of mortality in allo-HSCT [10], and the constitution of the intestinal microbiota at neutrophil engraftment and GM score can predict the development of aGvHD following myeloablative allo-HSCT [24, 25]. These results supported the idea for modulation of the GM in patients with HSCT. Modulation of the GM in HSCT After the confirmation of the strong impact of the GM on all aspects of HSCT, modulating GM composition in order to improve clinical outcomes has been proposed following different clinical trials. The main interventions described in the literature included two different potential strategies, preemptive and therapeutic, both of which have been used for preventing or treating GM dysbiosis during HSCT. Preemptive strategies include enteral nutrition (EN), prebiotic, probiotic, fecal microbiota transplantation (FMT) and antibiotic strategies, while therapeutic strategies include FMT, probiotic and lactoferrine usages [10] (Fig. 1).Fig. 1 Depiction of FMT mechanism. a HSCT and related procedures caused toxin secretion and intestinal epithelial cells damage. b FMT treatment made the microbiota diversity and intestinal epithelial cells recovery Nutritional supplementation in HSCT Nutrition support for patients includes two different kinds of options, EN and parenteral nutrition (PN). EN is a kind of nutritional support that provides nutrients and other nutrients needed by metabolism through the gastrointestinal tract. Meanwhile, PN is through intravenous injection into the blood circulation to supplement nutrition. Many studies have confirmed the connection between nutrition and the human microbiome in maintaining human health [26–30]. Traditionally, the first nutritional approach in post-HSCT patients is parenteral nutrition (PN), which is associated with several clinical adverse effects, supporting EN as a preferential alternative. The effect of PN and starvation on the intestinal ecosystem during HSCT has been studied and the results showed the decreased microbial richness and diversity [31, 32]. PN has been associated with the loss of commensal bacteria belonging to the genus Blautia and induces gut mucosal atrophy, promoting bacterial translocation and altering SCFA production [33–36]. Clinical data show that EN is associated with better outcomes in terms of survival, infection, and aGvHD [37–40]. Recent studies have showed that EN is a feasible and nutritionally adequate method of nutritional support for children undergoing allo-HSCT. EN can protect children undergoing allo-HSCT from blood stream infections [41] and promote the recovery of gut microbiome homeostasis [42]. In patients with EN, structural and functional probiotic GM distribution is rapidly restored after HSCT, which may reduce the risk of systemic infection and GvHD onset [42]. However, more studies are needed to further explore the role of the type of nutritional support in preserving GM during HSCT. These nutritional supports include applications of prebiotics, antibiotics, lactoferrin and probiotics. Prebiotics The first commonly used nutrition support option is prebiotics. Prebiotics are defined as ‘a substrate which is selectively utilized by host microorganisms conferring a health benefit’ [43]. This term usually refers to indigestible carbohydrates, such as dietary fibers, which are fermented in the colon by commensal bacteria to modify the microbiota and produce metabolites with potential immunomodulatory effects [44]. Examples of these fibers include resistant starches, fructooligosaccharides (including inulin), and galacto-oligosaccharides, which are found in a variety of foods including onions, oats, garlic, asparagus, and human milk. Different nutritional strategies have been explored in patients with HSCT in order to modify the GM. Tavil et al. utilized a diet richer in fibre in a patient in the pre-HSCT period, which correlated with earlier neutrophil engraftment and a shorter duration of febrile neutropenia [45]. Preemptive enteral supplementation with glutamine, fiber and oligosaccharide strategy is an effective supportive therapy to decrease the severity of mucosal damage in HSCT [46]. Currently, there is only one ongoing clinical trial using prebiotic to promote a healthy gut microbiome in pediatric HSCT recipients in the United States (NCT04111471). Prebiotics are metabolized by selected intestinal microorganisms and produce a variety of compounds through fermentation, including SCFAs butyrate, acetate and propionate. Several important studies highlighting the mechanism of prebiotics effect on gut mucosa and host immune response mediated by the intestinal microbiota [47]. SCFAs affect the host by (i) serving as a direct substrate for intestinal epithelial metabolism and maintenance of the mucosal barrier, (ii) affecting immune cell signaling and proliferation, (iii) altering epigenetic modifications, (iv) impacting microbial-microbial and microbial-host interactions, and (v) influencing chemotherapy efficacy and toxicity [47]. Butyrate and related SCFAs are major products of prebiotic metabolism. SCFAs can change the signaling of host immune cells: butyrate in the colonic lumen can increase the proliferation of host Tregs [48] and activate dendritic cells through signaling via chemokine G-protein–coupled receptors [49]. Thus it causes the differentiation of naive T cells into Tregs functions to suppress other immune cells that may induce inflammation. SCFAs can also act as HDAC inhibitors that change DNA structure and transcription, altering leukocytes and potentially affecting cancer [50] and infection risk [51]. Epigenetic changes have been increasingly implicated in hematologic malignancies like acute myeloid leukemia (AML) and may be affected by the GM. Prebiotics not only impact the risk of infection and GvHD, but also may influence chemotherapy efficacy and toxicity through cellular signaling pathways influenced by SCFA production in patients with cancer [52]. Emerging strategies for prebiotics have been developed in recent years by investigating non-fiber dietary supplements, such as vitamin A, on both microbiota composition and HSCT outcomes [43, 53]. One study showed that vitamin A levels in patients 30 days after HSCT predicted the incidence of GvHD and it may lead to the differentiation of naive T-cells into Tregs rather than Th17 cells, facilitating mucosal tolerance and improving mucosal barrier integrity [54]. Meanwhile, commensal bacteria may inhibit retinoid metabolism in the intestinal epithelium, reduce IL-22 levels and prevent dysbiosis [55]. The increased IL-22 level in children with GI aGvHD further supports the relationship between retinoic acid metabolism, IL-22 level and GvHD [56]. Table 1 summarizes the main on-going studies regarding dietary nutrition in HSCT. Especially, there are one completed (NCT03039257) and two ongoing clinical trials (NCT03202849, NCT03719092) with vitamin A supplementation in patients with HSCT (Table 1), and another ongoing trial directly administering IL-22 Fc as a potential therapy to attenuate GI GvHD (NCT02406651).Table 1 On-going dietary nutrition and HSCT related clinical trials Clinical trials. gov identifier Clinical trial title Phase Enrollment number Disease conditions Status Lead institution/location NCT03083327 Prophylactic Early PN in HPT/BMT Not applicable 408 Hematologic neoplasms Recruiting University of Sydney Australasian Bone Marrow Transplant Recipient Registry University of Roma La Sapienza NCT03534674 Vitamin D3 Supplementation for AlloHSCT-RCT Not applicable 84 Vitamin D deficiency Unknown Vancouver General Hospital Vancouver, British Columbia, Canada NCT03710031 Developing Self-Management Interventions After HCT Unknown 55 HSCT Recruiting University of Florida NCT02512718 Safety and Tolerability of Intravenous Fish Oil Lipid Emulsion in Children Undergoing Hematopoietic Cell Transplantation 1 20 HSCT Recruiting Boston Children's Hospital Boston, Massachusetts, United States NCT02763033 Dietary Manipulation of the Microbiome-metabolomic Axis for Mitigating GVHD in Allo HCT Patients 2 70 HSCT Recruiting University of Michigan Cancer Center Ann Arbor, Michigan, United States NCT03016130 Comparing Two Diets in Patients Undergoing HSCT or Remission Induction Chemo for Acute Leukemia and MDS (UF-BMT-LDND-101) 3 470 Leukemia Myelodysplastic syndromes Recruiting UF Health Cancer Center Gainesville, Florida, United States NCT03039257 Vitamin A Replacement in Patients Undergoing HSCT and Its Role on MBI-LCBI Rates Not applicable 12 HSCT Completed Cincinnati Children's Hospital Medical Center Cincinnati, Ohio, United States NCT03202849 A Randomized Trial of Vitamin D Supplementation With or Without Vitamin A in Stem Cell Transplantation Not applicable 100 HSCT Recruiting Cincinnati Children's Hospital Medical Center Cincinnati, Ohio, United States NCT03557749 Monitoring of Immune and Microbial Reconstitution in (HCT) and Novel Immunotherapies Not applicable 1600 Immune and microbial reconstitution Systemic viral infection GvHD Recruiting University of Minnesota Masonic Cancer Center Minneapolis, Minnesota, United States NCT03719092 High Dose Vitamin A in Preventing Gastrointestinal GVHD in Participants Undergoing Donor Stem Cell Transplant Not applicable 28 Allogeneic HSCT Not yet recruiting Ohio State University Comprehensive Cancer Center National Cancer Institute (NCI) NCT03727113 Optimization of Antibiotic Treatment in Hematopoietic Stem Cell Receptors Not applicable 180 HSCT GvHD Recruiting Virgen del Rocío University Hospital, Seville Sevilla, Seville, Spain NCT03918343 Lipopolysaccharide Metabolism and Identification of Potential Biomarkers Predictive of Graft-versus-host Disease After Allogeneic Stem Cell Transplantation Not applicable 98 Hematologic diseases HSCT Recruiting Centre Hospitalier Universitaire de Besançon Besançon, France Centre Hospitalier Universitaire de Nancy Nancy, France NCT04024618 Feasibility Study Comparing Enteral vs Parenteral Nutritional Outcomes in Autologous Stem Cell Transplant Patients Not applicable 40 Malignant hematologic neoplasm Recruiting London Health Sciences Centre-Victoria Hospital London, Ontario, Canada NCT04146870 Nutritional Status of Patients After Hematopoietic Stem Cell Transplantation Unknown 200 Nutrition HSCT Recruiting The First Affiliated Hospital of Soochow University NCT04172818 Feasibility Study of a Diary for Allogenic Hematopoietic Stem Cell Transplantation Patients and Families Not applicable 20 Hematopoietic/lymphoid cancer Psychological disorder Not yet recruiting CHU Amiens Amiens, France NCT04177004 Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant 1 36 Allogeneic HSCT Hematopoietic and lymphoid cell neoplasm Not yet recruiting City of Hope Medical Center Duarte, California, United States NCT02406651 Study of IL-22 IgG2-Fc (F-652) for Subjects With Grade II-IV Lower GI aGVHD 1,2 27 GvHD Active, not recruiting City of Hope Duarte, California, United States NCT04425642 Effects of Parenteral Nutrition in HSCT Not applicable 120 Hematologic malignancy Recruiting Pavlov First Saint-Petersburg State Medical University Saint Petersburg, Russian Federation Lactoferrin Lactoferrin, a glycoprotein of transferrin family, is an iron-binding protein with pleiotropic functions, such as antianemic, antimicrobial, anti-inflammatory, immunoregulatory, antioxidant, and anti-cancer activity, and is also involved in intestinal epithelial regeneration and iron homeostasis [57]. Recently, lactoferrin has been used as new specific molecule in dysbiosis prevention. Lactoferrin and N-terminal peptide-derivatives have been studied in preclinical models, and can reduce bacterial translocation, improving GM eubiosis [58, 59]. Administration of lactoferrin in an HSCT patient showed that symptoms of gut GvHD disappeared soon after lactoferrin therapy was started [60]. Introduction of probiotics with a regimen containing bovine lactoferrin for preterm infants in New Zealand has been associated with significant reductions in necrotizing enterocolitis (NEC) and late onset sepsis [61]. A pooled analysis of individual patient data from two randomized controlled trials demonstrated bovine lactoferrin supplementation protects against late-onset sepsis in infants < 1500 g, especially among infants not receiving human milk [62]. Study by using probiotic and lactoferrin prebiotic were administered in mice showed both Clostridioides difficile inoculation and treatment with vancomycin or fidaxomicin reduced microbiota diversity; however, dysbiosis associated with fidaxomicin was milder than with vancomycin [63]. The use of lactoferrin, or short peptide derivatives that retain the cationic N-terminal moiety that is essential for the anti-microbial and anti-inflammatory activity, may prove to be a promising versatile class of agents for managing the complications that arise from HSCT [64]. Lactoferrin has also been used for many other different clinical applications and has more potential perspectives on its prophylactic and therapeutic applications in the future [57]. Additionally, lactoferrin offers a promising biodegradable well tolerated material that could be exploited both as an active therapeutic and drug nanocarrier. Lactoferrin-based nanocarriers have been demonstrated as efficient platforms for delivery of anti-parkinsonian, anti-Alzheimer, anti-viral drugs, immunomodulatory and bone engineering applications [65]. Probiotics Another commonly used nutrition support option is probiotics. Probiotics consist of traditional and commonly eaten foods, and are defined by the Food and Agriculture Organization of the United Nations (FAO) and the World Health Organization (WHO) as ‘live microorganisms which when administered in adequate amounts, confer a health benefit on the host’ [66]. A probiotic-rich diet prior to HSCT is associated with earlier neutrophil engraftment and a shorter duration of febrile neutropenia [45]. However, in a randomized probiotic enteric regimen trial, supplementation of Lactobacillus rhamnosus GG in patients with allo-HSCT showed no significant change in GM or protection against GvHD [67]. In another phase II trial, which lacked a control group, prophylactic use of Lactobacillus brevis CD2 lozenges appeared to reduce the incidence, duration and severity of oral mucositis [68]. Recent study supports the safe use of probiotics in a high-risk population of pediatric HSCT patients with compromised intestinal mucosal integrity [69]. On the other hand, for immune compromised patients with related symptoms and some changes in intestinal permeability, there are some concerns regarding the safety of probiotics administration. For instance, it has been reported bacteremia and sepsis caused by pathogens normally considered being probiotics [70], and infection resulted in meningitis in one report of a child undergoing HSCT [71]. However, data analysis of HSCT patients supports the safety of probiotics, suggesting that organisms frequently included in over-the-counter probiotics are a rare cause of bacteremia after HSCT [72], indicating the safety and feasibility of probiotic Lactobacillus plantarum in children and adolescents receiving HSCT treatment, without associated bacteremia or adverse events [73]. FMT FMT refers to the infusion of feces from healthy donors into the gastrointestinal tract of recipient patients with dysbiotic GM. FMT was first found to be effective for the treatment of recurrent Clostridium difficile infections (rCDI). It is currently being evaluated in many different fields, including HSCT [74]. It is considered as the "ultimate probiotics" by some authors because it directly changes the intestinal microbial composition of the host, thus restoring eubiosis and intestinal homeostasis [75, 76]. Table 2 summarizes the main on-going studies regarding FMT and microbiota in HSCT (Table 2). The source of fecal materials can be either healthy donors or the patient themselves. Clinical findings point toward a beneficial effect of FMT to improve GvHD and HIV-related outcomes through the engraftment of beneficial donor bacteria, notably those producing anti-inflammatory metabolites [77]. Clinical trials results indicate that empiric third-party FMT after allo-HCT appears to be feasible, safe, and associated with expansion of recipient microbiome diversity [78].Table 2 FMT and Microbiota related clinical trials Clinical TRIALS. gov identifier Clinical trial title Phase Enrollment number Disease conditions Status Lead institution/location NCT02641236 Gut Decontamination in Pediatric Allogeneic Hematopoietic 2 28 HSCT, aGvHD Recruiting Boston Children's Hospital Boston, Massachusetts, United States NCT03148197 Changes in the Gut Microbiota of Patients Undergoing Allogeneic Stem Cell Transplantation (COLLECT) 1, 2 30 AML, GvHD, Allogeneic HSCT, HSCT complications Unknown University Hospital of Cologne Cologne, Germany NCT03214289 Fecal Microbiota Transplantation for Steroid Resistant and Steroid Dependent Gut Acute Graft Versus Host Disease 1 4 HSCT complications GvHD, Acute FMT Unknown Chaim Sheba Medical Center Ramat Gan, Israel NCT03616015 Dysbiosis and Immune Reconstitution After Allo-HSCT Not applicable 80 HSCT Recruiting RUBIO Marie-Thérèse Vandoeuvre Les Nancy, France NCT03678493 A Study of FMT in Patients With AML Allo HSCT in Recipients 2 120 AML, Allogeneic HSCT Recruiting Masonic Cancer Center at University of Minnesota Minneapolis, Minnesota, United States NCT03720392 Fecal Microbiota Transplantation (FMT) in Recipients After Allogeneic Hematopoietic Cell Transplantation (HCT) 2 48 Allogeneic HSCT Active, not recruiting Massachusetts General Hospital Cancer Center Boston, Massachusetts, United States NCT03812705 Fecal Microbiota Transplantation for Steroid Resistant/Dependent Acute GI GVHD 2 30 Hematopoietic and lymphoid cell neoplasm Recruiting Shanghai Jiao Tong University Affilated First People's Hospital, Shanghai, Shanghai, China NCT03819803 Fecal Microbiota Transplantation in aGvHD After ASCT 3 15 GvHD in GI Tract Recruiting Division of Gastroenterology and Hepatology, Department of Internal Medicine, Medical University of Graz Graz, Styria, Austria NCT04111471 The Use of A Prebiotic to Promote a Healthy Gut Microbiome in Pediatric Stem Cell Transplant Recipients Not applicable 40 Microbial colonization Recruiting Ann & Robert H Lurie Children's Hospital of Chicago Chicago, Illinois, United States NCT04139577 FMT In High-Risk Acute GVHD After ALLO HCT 1 11 aGvHD, HSCT, FMT Not yet recruiting Dana Farber Cancer Institute Boston, Massachusetts, United States NCT04203017 Fecal Microbiota Transplantation After Autologous HSCT in Patients With Multiple Sclerosis 1 20 Multiple Sclerosis Recruiting Pavlov First Saint-Petersburg State Medical University Saint Petersburg, Russian Federation NCT04269850 Fecal Microbiota Transplantation With Ruxolitinib and Steroids as an Upfront Treatment of Severe Acute Intestinal GVHD 1, 2 20 Intestinal GVHD Recruiting Pavlov First Saint-Petersburg State Medical University Saint Petersburg, Russian Federation NCT04281797 Intestinal Microbiome Dynamics in Solid Organ and Stem Cell Transplant Recipients Not applicable 90 Transplantation infection Kidney transplant; Complications HSCT complications Enrolling by invitation Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology Minsk, Belarus NCT04285424 FMT for Steroid Resistant Gut Acute GVHD 1 30 HSCT complications aGvHD, FMT Recruiting Affiliated Hospital to Academy of Military Medical Sciences, Beijing, Beijing, China Recent study demonstrated that donor FMT can ameliorates intestinal GvHD in allo-HSCT recipients [79], which is an effective and safe method for the treatment of refractory diarrhea after allo-HSCT [80]. A single-center pilot study showed that Longitudinal analysis of fecal microbiome and metabolites after HSCT identified butyrate and indole as potential surrogate markers for microbial diversity and specific taxa. However, further studies are needed to ascertain whether fecal metabolites can be used as biomarkers of acute intestinal GvHD or bacteremia after HSCT [81]. Furthermore, in patients carrying or infected by multidrug-resistant bacteria, FMT is an effective and safe decolonization strategy, even in those with hematologic malignancies undergoing HSCT [82]. FMT in the treatment of intestinal steroid-resistant GvHD have been evaluated with very promising results [83, 84]. Recent studies have demonstrated the early GM signature of aGvHD in children given allo-HSCT for hematological disorders. Children developing GI aGvHD had a dysbiotic GM layout before HSCT occurred. This putative aGvHD-predisposing ecosystem state was characterized by (i) reduced diversity, (ii) lower Blautia content, (iii) increase in Fusobacterium abundance. At time of engraftment, the GM structure underwent a deep rearrangement in all patients and reacquired a eubiotic configuration from day 30. This specific GM signature before HSCT predictive of subsequent GI aGvHD occurrence may be useful for GM-based stratification of the risk of developing aGvHD in children undergoing HSCT, potentially also useful to identify patients benefiting from prophylactic FMT [85]. Due to the genetic similarity and shared environment, a related FMT donor may have a GM composition closer to the recipient’s before the HSCT-induced dysbiosis. However, related FMT donors need time to screen, collect, and process, whereas unrelated healthy FMT donors fecal material can be collected and stored frozen in a stool bank for use when needed [76]. Donor screening is a key factor in the safety of the procedure in order to prevent iatrogenic infectious diseases potentially transmittable to the recipient [75]. Different ways of administering FMT, such as colonoscopy, esophago-gastro-duodenoscopy, nasogastric or naso-duodenal tube, enema, and oral capsule can be used without superiority over each other [86]. Oral capsule seems to maintain the efficacy and safety of other routes, and is less invasive for the patient [87], with the feasibility for a substantial number of capsules to achieve the necessary microbial load [88]. Although it’s important to use different methods to treat the HSCT-induced dysbiosis, maintaining Bacteroides during allo-HSCT is the best practice strategy for the prevention of aGvHD [89]. Different options provide promising and practical results in clinical treatment. However, there is no evidence that prophylactic FMT improves clinical outcomes, and larger clinical trials are needed to further determine the standard treatment procedure for aGVHD patients using FMT. Mechanism of FMT Although FMT has been successfully used to treat diseases including GvHD and other recurrent or refractory Clostridium difficile infection (rCDI) [90], the mechanisms by which it exerts its therapeutic effects have not yet been fully elucidated. Most researchers leaned to the competitive exclusion of the pathogen with the microbiota outcompeting C. difficile for nutrients and creating an environment that is unfavorable for its growth [91]. The dysbiosis that caused by HSCT and related procedures (conditioning regimen, antibiotic exposure, diet, anti-acid prophylaxis) as a combination of upsetting events, which profoundly modify the GM structure, leading to disruption of healthy environment for microbiota. The efficacy of FMT for rCDI through competitive exclusion is thought to occur in part through the modulation of bile-salt metabolism, which affects C. difficile spore germination. Also, FMT may also exert its therapeutic effect by increasing sialic-acid utilization by commensal bacteria, thus depriving C. difficile of a vital energy source. Other possible mechanism includes: protease activity inactivating secreted C. difficile toxins, stimulation of host-cell defenses through release of small molecules such as short-chain fatty acids, and direct activity against C. difficile viability through bacteriocin-like mechanisms [90]. These potentially mechanisms of FMT against C. difficile remain to be fully elucidated and are summarized in Fig. 1. Antibiotics Antibiotics are another commonly used support option in GvHD patients. Based on the early results that GvHD is unlikely to occur in germ-free mice [92], GI decontamination using non-absorbable antibiotics was introduced in HSCT recipients. However, the mixed results were demonstrated by different studies [93, 94]. Recently, GM dynamics were analyzed in patients undergoing gut decontamination, comparing results in children receiving total or selective decontamination. In both groups, GM richness and diversity decreased markedly, but were restored gradually after cessation of antibiotics [95]. Using ciprofloxacin and metronidazole, or rifaximin only for gut decontamination, studies revealed a significant reduction in gut GvHD and 1-year transplant related mortality, and a significant increase in overall survival, with less enterococcal load and higher urinary 3-indoxyl sulfate concentrations in the rifaximin group [96–98]. Furthermore, treatment of infectious complications with systemic antibiotics did not abrogate the beneficial effects of rifaximin on GM composition and on HSCT outcomes [99]. Though antibiotics have undoubtedly mitigated the risk of adverse outcomes attributed to infections, recent studies suggest that early broad-spectrum antibiotic use is an independent risk factor for increased mortality in allo-HSCT recipients [19, 100, 101]. Cumulative exposure to penicillin derivatives and carbapenem antibiotics was associated with a higher incidence rate of GI aGvHD [102]. In particular, piperacillin-tazobactam and imipenem-cilastatin were associated with increased incidence, severity, and mortality in gut GvHD [100], especially in patients receiving fourth-generation cephalosporins [103]. Recent study demonstrate that exposure to anaerobic antibiotics is associated with increased risks of acute gut/liver GvHD and acute GvHD mortality after allo-HSCT [104]. Recent Meta-analysis also confirmed that gut decontamination and prophylaxis with systemic antibiotics increase acute and intestinal GVHD, with a significant effect of microbiota diversity on treatment-related mortality and overall survival [105]. Conclusion The advances of microbiome in HSCT enabled us to better understand the relationship between GM and GVHD, as well as the clinical treatment strategies of GM for GvHD patients. The clinical application of microbiota, as predictor of mortality in allo-HSCT and as therapeutic strategies with targeted modulation of GM, has been used for preventing or treating GM dysbiosis in patients with HSCT in the past years. However, there is still much work to be done in order to better comprehend the precise biological mechanism and the overall clinical impact of a specific dysbiosis pattern. With more advances with the possible microbiota-altering preventive and therapeutic strategies, the potential of modulating the microbiome to improve outcome of GvHD in patients with HSCT will come true soon. Abbreviations aGvHDAcute graft versus host disease allo-HSCTAllogeneic hematopoietic stem cell transplantation AMLAcute myeloid leukemia ENEnteral nutrition FAOFood and Agriculture Organization of the United Nations FMTFecal microbiota transplantation GIGastro-intestinal GMGut microbiota GvHDGraft versus host disease HDACHistone deacetylase HSCTHematopoietic stem-cell transplantation NECNecrotizing enterocolitis rCDIRecurrent or refractory Clostridium difficile infection SCFAShort-chain fatty acid TregsRegulatory T cells WHOWorld Health Organization Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Jifeng Yu and Hao Sun contributed equally to this work Acknowledgements We thank Dr. Delong Liu of New York Medical College and Dr. Peter Y.Z. Jiang of The Everett Clinic and Providence Regional Medical Center in USA for helpful discussion. Authors’ contributions All authors contributed to drafting and revising the article and agree to be accountable for all aspects of the work. All authors read and approved the final manuscript. Funding This study was funded by the Key Scientific Research Project of Henan Provincial Education Department (20A320062), Jointly Sponsored Project of Henan Medical Science and Technology Research Plan of 2019 (LHGJ20190039) and Special Talents Project Fund of the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China. The funding bodies did not participate in study design, in data collection, analysis, and interpretation, and in writing the manuscript. Availability of data and materials Not applicable. Ethics approval and consent to participate Not applicable. Consent for publication Not applicable. Competing interests The authors declare that they have no competing interests. ==== Refs References 1. The Integrative HMP (iHMP) Research Network Consortium The Integrative Human Microbiome Project Nature 2019 569 7758 641 648 10.1038/s41586-019-1238-8 31142853 2. Mazmanian SK Liu CH Tzianabos AO Kasper DL An immunomodulatory molecule of symbiotic bacteria directs maturation of the host immune system Cell 2005 122 1 107 118 10.1016/j.cell.2005.05.007 16009137 3. Karlsson FH Tremaroli V Nookaew I Bergström G Behre CJ Fagerberg B Gut metagenome in European women with normal, impaired and diabetic glucose control Nature 2013 498 7452 99 103 10.1038/nature12198 23719380 4. Abrahamsson TR Jakobsson HE Andersson AF Björkstén B Engstrand L Jenmalm MC Low gut microbiota diversity in early infancy precedes asthma at school age Clin Exp Allergy 2014 44 6 842 850 10.1111/cea.12253 24330256 5. Holler E Butzhammer P Schmid K Hundsrucker C Koestler J Peter K Metagenomic analysis of the stool microbiome in patients receiving allogeneic stem cell transplantation: loss of diversity is associated with use of systemic antibiotics and more pronounced in gastrointestinal graft-versus-host disease Biol Blood Marrow Transplant 2014 20 5 640 645 10.1016/j.bbmt.2014.01.030 24492144 6. Jenq RR Ubeda C Taur Y Menezes CC Khanin R Dudakov JA Regulation of intestinal inflammation by microbiota following allogeneic bone marrow transplantation J Exp Med 2012 209 5 903 911 10.1084/jem.20112408 22547653 7. Biagi E Zama D Nastasi C Consolandi C Fiori J Rampelli S Gut microbiota trajectory in pediatric patients undergoing hematopoietic SCT Bone Marrow Transplant 2015 50 7 992 998 10.1038/bmt.2015.16 25893458 8. Peled JU Devlin SM Staffas A Lumish M Khanin R Littmann ER Intestinal microbiota and relapse after hematopoietic-cell transplantation J Clin Oncol 2017 35 15 1650 1659 10.1200/JCO.2016.70.3348 28296584 9. Peled JU Gomes ALC Devlin SM Littmann ER Taur Y Sung AD Microbiota as predictor of mortality in allogeneic hematopoietic-cell transplantation N Engl J Med 2020 382 9 822 834 10.1056/NEJMoa1900623 32101664 10. Zama D Bossù G Leardini D Muratore E Biagi E Prete A Insights into the role of intestinal microbiota in hematopoietic stem-cell transplantation Ther Adv Hematol 2020 11 2040620719896961 10.1177/2040620719896961 32010434 11. Magenau J Runaas L Reddy P Advances in understanding the pathogenesis of graft-versus-host disease Br J Haematol 2016 173 2 190 205 10.1111/bjh.13959 27019012 12. Washington K Jagasia M Pathology of graft-versus-host disease in the gastrointestinal tract Hum Pathol 2009 40 7 909 917 10.1016/j.humpath.2009.04.001 19524102 13. Kambham N Higgins JP Sundram U Troxell ML Hematopoietic stem cell transplantation: graft versus host disease and pathology of gastrointestinal tract, liver, and lung Adv Anat Pathol 2014 21 5 301 320 10.1097/PAP.0000000000000032 25105933 14. Belkaid Y Hand TW Role of the microbiota in immunity and inflammation Cell 2014 157 1 121 141 10.1016/j.cell.2014.03.011 24679531 15. Vinolo MA Rodrigues HG Nachbar RT Curi R Regulation of inflammation by short chain fatty acids Nutrients 2011 3 10 858 876 10.3390/nu3100858 22254083 16. Michonneau D Latis E Curis E Dubouchet L Ramamoorthy S Ingram B Metabolomics analysis of human acute graft-versus-host disease reveals changes in host and microbiota-derived metabolites Nat Commun 2019 10 1 5695 10.1038/s41467-019-13498-3 31836702 17. Payen M Nicolis I Robin M Michonneau D Delannoye J Mayeur C Functional and phylogenetic alterations in gut microbiome are linked to graft-versus-host disease severity Blood Adv 2020 4 9 1824 1832 10.1182/bloodadvances.2020001531 32353108 18. Ouyang W Kolls JK Zheng Y The biological functions of T helper 17 cell effector cytokines in inflammation Immunity 2008 28 4 454 467 10.1016/j.immuni.2008.03.004 18400188 19. Taur Y Jenq RR Perales MA Littmann ER Morjaria S Ling L The effects of intestinal tract bacterial diversity on mortality following allogeneic hematopoietic stem cell transplantation Blood 2014 124 7 1174 1182 10.1182/blood-2014-02-554725 24939656 20. Taur Y Xavier JB Lipuma L Ubeda C Goldberg J Gobourne A Intestinal domination and the risk of bacteremia in patients undergoing allogeneic hematopoietic stem cell transplantation Clin Infect Dis 2012 55 7 905 914 10.1093/cid/cis580 22718773 21. Lee SE Lim JY Ryu DB Kim TW Park SS Jeon YW Alteration of the intestinal microbiota by broad-spectrum antibiotic use correlates with the occurrence of intestinal graft-versus-host disease Biol Blood Marrow Transplant 2019 25 10 1933 1943 10.1016/j.bbmt.2019.06.001 31195137 22. Ferrara JL Smith CM Sheets J Reddy P Serody JS Altered homeostatic regulation of innate and adaptive immunity in lower gastrointestinal tract GVHD pathogenesis J Clin Invest 2017 127 7 2441 2451 10.1172/JCI90592 28581444 23. Chong PP Koh AY The gut microbiota in transplant patients Blood Rev 2020 39 100614 10.1016/j.blre.2019.100614 31492463 24. Han L Zhang H Chen S Zhou L Li Y Zhao K Intestinal microbiota can predict acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation Biol Blood Marrow Transplant 2019 25 10 1944 1955 10.1016/j.bbmt.2019.07.006 31299215 25. Han L Zhao K Li Y Han H Zhou L Ma P A gut microbiota score predicting acute graft-versus-host disease following myeloablative allogeneic hematopoietic stem cell transplantation Am J Transplant 2020 20 4 1014 1027 10.1111/ajt.15654 31605563 26. Cotillard A Kennedy SP Kong LC Prifti E Pons N Le Chatelier E Dietary intervention impact on gut microbial gene richness Nature 2013 500 7464 585 588 10.1038/nature12480 23985875 27. Dao MC Everard A Aron-Wisnewsky J Sokolovska N Prifti E Verger EO Akkermansia muciniphila and improved metabolic health during a dietary intervention in obesity: relationship with gut microbiome richness and ecology Gut 2016 65 3 426 436 10.1136/gutjnl-2014-308778 26100928 28. David LA Maurice CF Carmody RN Gootenberg DB Button JE Wolfe BE Diet rapidly and reproducibly alters the human gut microbiome Nature 2014 505 7484 559 563 10.1038/nature12820 24336217 29. Krezalek MA Yeh A Alverdy JC Morowitz M Influence of nutrition therapy on the intestinal microbiome Curr Opin Clin Nutr Metab Care 2017 20 2 131 137 10.1097/MCO.0000000000000348 27997410 30. Liou AP Paziuk M Luevano JM Jr. Machineni S Turnbaugh PJ Kaplan LM Conserved shifts in the gut microbiota due to gastric bypass reduce host weight and adiposity Sci Transl Med. 2013 5 178 178ra41 10.1126/scitranslmed.3005687 23536013 31. Mack I Penders J Cook J Dugmore J Mazurak N Enck P Is the impact of starvation on the gut microbiota specific or unspecific to anorexia nervosa? A narrative review based on a systematic literature search Curr Neuropharmacol 2018 16 8 1131 1149 10.2174/1570159X16666180118101354 29345582 32. Seitz J Belheouane M Schulz N Dempfle A Baines JF Herpertz-Dahlmann B The impact of starvation on the microbiome and gut-brain interaction in anorexia nervosa Front Endocrinol 2019 10 41 10.3389/fendo.2019.00041 33. Jenq RR Taur Y Devlin SM Ponce DM Goldberg JD Ahr KF Intestinal blautia is associated with reduced death from graft-versus-host disease Biol Blood Marrow Transplant 2015 21 8 1373 1383 10.1016/j.bbmt.2015.04.016 25977230 34. MacFie J Reddy BS Gatt M Jain PK Sowdi R Mitchell CJ Bacterial translocation studied in 927 patients over 13 years Br J Surg 2006 93 1 87 93 10.1002/bjs.5184 16288452 35. Pierre JF Gastrointestinal immune and microbiome changes during parenteral nutrition Am J Physiol Gastrointest Liver Physiol 2017 312 3 G246 G256 10.1152/ajpgi.00321.2016 28154012 36. Ríos-Covián D Ruas-Madiedo P Margolles A Gueimonde M de Los Reyes-Gavilán CG Salazar N Intestinal short chain fatty acids and their link with diet and human health Front Microbiol 2016 7 185 10.3389/fmicb.2016.00185 26925050 37. Azarnoush S Bruno B Beghin L Guimber D Nelken B Yakoub-Agha I Enteral nutrition: a first option for nutritional support of children following allo-SCT? Bone Marrow Transplant 2012 47 9 1191 1195 10.1038/bmt.2011.248 22231466 38. Gonzales F Bruno B Alarcón Fuentes M De Berranger E Guimber D Behal H Better early outcome with enteral rather than parenteral nutrition in children undergoing MAC allo-SCT Clin Nutr. 2018 37 6 Pt A 2113 21 10.1016/j.clnu.2017.10.005 29097037 39. Guièze R Lemal R Cabrespine A Hermet E Tournilhac O Combal C Enteral versus parenteral nutritional support in allogeneic haematopoietic stem-cell transplantation Clin Nutr 2014 33 3 533 538 10.1016/j.clnu.2013.07.012 23938114 40. Seguy D Duhamel A Rejeb MB Gomez E Buhl ND Bruno B Better outcome of patients undergoing enteral tube feeding after myeloablative conditioning for allogeneic stem cell transplantation Transplantation 2012 94 3 287 294 10.1097/TP.0b013e3182558f60 22785249 41. Zama D Muratore E Biagi E Forchielli ML Rondelli R Candela M Enteral nutrition protects children undergoing allogeneic hematopoietic stem cell transplantation from blood stream infections Nutr J 2020 19 1 29 10.1186/s12937-020-00537-9 32276595 42. D'Amico F Biagi E Rampelli S Fiori J Zama D Soverini M Enteral nutrition in pediatric patients undergoing hematopoietic SCT promotes the recovery of gut microbiome homeostasis Nutrients. 2019 11 12 2958 10.3390/nu11122958 6950621 43. Gibson GR Hutkins R Sanders ME Prescott SL Reimer RA Salminen SJ Expert consensus document: The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics Nat Rev Gastroenterol Hepatol 2017 14 8 491 502 10.1038/nrgastro.2017.75 28611480 44. Shono Y van den Brink MRM Gut microbiota injury in allogeneic haematopoietic stem cell transplantation Nat Rev Cancer 2018 18 5 283 295 10.1038/nrc.2018.10 29449660 45. Tavil B Koksal E Yalcin SS Uckan D Pretransplant nutritional habits and clinical outcome in children undergoing hematopoietic stem cell transplant Exp Clin Transplant 2012 10 1 55 61 10.6002/ect.2011.0082 22309421 46. Iyama S Sato T Tatsumi H Hashimoto A Tatekoshi A Kamihara Y Efficacy of enteral supplementation enriched with glutamine, fiber, and oligosaccharide on mucosal injury following hematopoietic stem cell transplantation Case Rep Oncol 2014 7 3 692 699 10.1159/000368714 25493082 47. Severyn CJ Brewster R Andermann TM Microbiota modification in hematology: still at the bench or ready for the bedside? Blood Adv 2019 3 21 3461 3472 10.1182/bloodadvances.2019000365 31714965 48. Smith PM Howitt MR Panikov N Michaud M Gallini CA Bohlooly YM The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis Science 2013 341 6145 569 573 10.1126/science.1241165 23828891 49. Kaisar MMM Pelgrom LR van der Ham AJ Yazdanbakhsh M Everts B Butyrate conditions human dendritic cells to prime type 1 regulatory T cells via both histone deacetylase inhibition and g protein-coupled receptor 109A signaling Front Immunol 2017 8 1429 10.3389/fimmu.2017.01429 29163504 50. Qin Y Wade PA Crosstalk between the microbiome and epigenome: messages from bugs J Biochem 2018 163 2 105 112 10.1093/jb/mvx080 29161429 51. Schulthess J Pandey S Capitani M Rue-Albrecht KC Arnold I Franchini F The short chain fatty acid butyrate imprints an antimicrobial program in macrophages Immunity 2019 50 2 432 45.e7 10.1016/j.immuni.2018.12.018 30683619 52. Schoener CA Carillo-Conde B Hutson HN Peppas NA An inulin and doxorubicin conjugate for improving cancer therapy J Drug Deliv Sci Technol 2013 23 2 111 118 10.1016/S1773-2247(13)50018-9 24734120 53. Conserva MR Anelli L Zagaria A Specchia G Albano F The pleiotropic role of retinoic acid/retinoic acid receptors signaling: from vitamin a metabolism to gene rearrangements in acute promyelocytic leukemia Int J Mol Sci. 2019 20 12 2921 10.3390/ijms20122921 6627493 54. Lounder DT Khandelwal P Dandoy CE Jodele S Grimley MS Wallace G Lower levels of vitamin A are associated with increased gastrointestinal graft-versus-host disease in children Blood 2017 129 20 2801 2807 10.1182/blood-2017-02-765826 28279965 55. Grizotte-Lake M Zhong G Duncan K Kirkwood J Iyer N Smolenski I Commensals suppress intestinal epithelial cell retinoic acid synthesis to regulate interleukin-22 activity and prevent microbial dysbiosis Immunity 2018 49 6 1103 15.e6 10.1016/j.immuni.2018.11.018 30566883 56. Lounder DT Khandelwal P Gloude NJ Dandoy CE Jodele S Medvedovic M Interleukin-22 levels are increased in gastrointestinal graft-versus-host disease in children Haematologica 2018 103 10 e480 e482 10.3324/haematol.2017.174771 29773594 57. Superti F Lactoferrin from bovine milk: a protective companion for life Nutrients. 2020 12 9 2562 10.3390/nu12092562 7551115 58. Drago-Serrano ME Campos-Rodriguez R Carrero JC de la Garza M Lactoferrin and peptide-derivatives: antimicrobial agents with potential use in nonspecific immunity modulation Curr Pharm Des 2018 24 10 1067 1078 10.2174/1381612824666180327155929 29589540 59. Haiwen Z Rui H Bingxi Z Qingfeng G Jifeng Z Xuemei W Oral Administration of bovine lactoferrin-derived lactoferricin (Lfcin) B could attenuate enterohemorrhagic Escherichia coli O157:H7 induced intestinal disease through improving intestinal barrier function and microbiota J Agric Food Chem 2019 67 14 3932 3945 10.1021/acs.jafc.9b00861 30892034 60. Inoue M Okamura T Yasui M Sakata N Yagi K Kawa K Lactoferrin for gut GVHD Bone Marrow Transplant 2001 28 11 1091 1092 10.1038/sj.bmt.1703283 11781622 61. Meyer MP Chow SSW Alsweiler J Bourchier D Broadbent R Knight D Probiotics for prevention of severe necrotizing enterocolitis: experience of New Zealand neonatal intensive care units Front Pediatr 2020 8 119 10.3389/fped.2020.00119 32318522 62. Ochoa TJ Loli S Mendoza K Carcamo C Bellomo S Cam L Effect of bovine lactoferrin on prevention of late-onset sepsis in infants <1500g: a pooled analysis of individual patient data from two randomized controlled trials Biochem Cell Biol. 2020 10.1139/bcb-2020-0046 32931708 63. Yamaguchi T Konishi H Aoki K Ishii Y Chono K Tateda K The gut microbiome diversity of Clostridioides difficile-inoculated mice treated with vancomycin and fidaxomicin J Infect Chemother 2020 26 5 483 491 10.1016/j.jiac.2019.12.020 32165071 64. van der Velden WJ Blijlevens NM Donnelly JP The potential role of lactoferrin and derivatives in the management of infectious and inflammatory complications of hematology patients receiving a hematopoietic stem cell transplantation Transpl Infect Dis 2008 10 2 80 89 10.1111/j.1399-3062.2007.00260.x 17605731 65. Elzoghby AO Abdelmoneem MA Hassanin IA Abd Elwakil MM Elnaggar MA Mokhtar S Lactoferrin, a multi-functional glycoprotein: active therapeutic, drug nanocarrier & targeting ligand Biomaterials 2020 263 120355 10.1016/j.biomaterials.2020.120355 32932142 66. Hill C Guarner F Reid G Gibson GR Merenstein DJ Pot B Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic Nat Rev Gastroenterol Hepatol. 2014 11 8 506 14 10.1038/nrgastro.2014.66 24912386 67. Gorshein E Wei C Ambrosy S Budney S Vivas J Shenkerman A Lactobacillus rhamnosus GG probiotic enteric regimen does not appreciably alter the gut microbiome or provide protection against GVHD after allogeneic hematopoietic stem cell transplantation Clin Transplant. 2017 10.1111/ctr.12947 28256022 68. Sharma A Tilak T Bakhshi S Raina V Kumar L Chaudhary SP Lactobacillus brevis CD2 lozenges prevent oral mucositis in patients undergoing high dose chemotherapy followed by haematopoietic stem cell transplantation ESMO Open 2016 1 6 e000138 10.1136/esmoopen-2016-000138 28848667 69. Sadanand A Newland JG Bednarski JJ Safety of probiotics among high-risk pediatric hematopoietic stem cell transplant recipients Infect Dis Ther 2019 8 2 301 306 10.1007/s40121-019-0244-3 30989592 70. Mehta A Rangarajan S Borate U A cautionary tale for probiotic use in hematopoietic SCT patients-Lactobacillus acidophilus sepsis in a patient with mantle cell lymphoma undergoing hematopoietic SCT Bone Marrow Transplant 2013 48 3 461 462 10.1038/bmt.2012.153 22890287 71. Robin F Paillard C Marchandin H Demeocq F Bonnet R Hennequin C Lactobacillus rhamnosus meningitis following recurrent episodes of bacteremia in a child undergoing allogeneic hematopoietic stem cell transplantation J Clin Microbiol 2010 48 11 4317 4319 10.1128/JCM.00250-10 20844225 72. Cohen SA Woodfield MC Boyle N Stednick Z Boeckh M Pergam SA Incidence and outcomes of bloodstream infections among hematopoietic cell transplant recipients from species commonly reported to be in over-the-counter probiotic formulations Transpl Infect Dis 2016 18 5 699 705 10.1111/tid.12587 27501401 73. Ladas EJ Bhatia M Chen L Sandler E Petrovic A Berman DM The safety and feasibility of probiotics in children and adolescents undergoing hematopoietic cell transplantation Bone Marrow Transplant 2016 51 2 262 266 10.1038/bmt.2015.275 26569091 74. Rao K Safdar N Fecal microbiota transplantation for the treatment of Clostridium difficile infection J Hosp Med 2016 11 1 56 61 10.1002/jhm.2449 26344412 75. Cammarota G Ianiro G Tilg H Rajilić-Stojanović M Kump P Satokari R European consensus conference on faecal microbiota transplantation in clinical practice Gut 2017 66 4 569 580 10.1136/gutjnl-2016-313017 28087657 76. DeFilipp Z Hohmann E Jenq RR Chen YB Fecal microbiota transplantation: restoring the injured microbiome after allogeneic hematopoietic cell transplantation Biol Blood Marrow Transplant 2019 25 1 e17 e22 10.1016/j.bbmt.2018.10.022 30408565 77. Ouyang J Isnard S Lin J Fombuena B Peng X Nair Parvathy S Treating from the inside out: relevance of fecal microbiota transplantation to counteract gut damage in GVHD and HIV infection Front Med 2020 7 421 10.3389/fmed.2020.00421 78. DeFilipp Z Peled JU Li S Mahabamunuge J Dagher Z Slingerland AE Third-party fecal microbiota transplantation following allo-HCT reconstitutes microbiome diversity Blood Adv 2018 2 7 745 753 10.1182/bloodadvances.2018017731 29592876 79. van Lier YF Davids M Haverkate NJE de Groot PF Donker ML Meijer E Donor fecal microbiota transplantation ameliorates intestinal graft-versus-host disease in allogeneic hematopoietic cell transplant recipients Sci Transl Med. 2020 12 556 eaaz8926 10.1126/scitranslmed.aaz8926 32801142 80. Wang Q Fu YW Wang YQ Ai H Yuan FF Wei XD Fecal microbiota transplantation for patients with refractory diarrhea after allogeneic hematopoietic stem cell transplantation Zhonghua Xue Ye Xue Za Zhi 2019 40 10 853 855 31775486 81. Galloway-Peña JR Peterson CB Malik F Sahasrabhojane PV Shah DP Brumlow CE Fecal microbiome, metabolites, and stem cell transplant outcomes: a single-center pilot study Open Forum Infect Dis. 2019 6 5 ofz173 10.1093/ofid/ofz173 31065565 82. Battipaglia G Malard F Rubio MT Ruggeri A Mamez AC Brissot E Fecal microbiota transplantation before or after allogeneic hematopoietic transplantation in patients with hematologic malignancies carrying multidrug-resistance bacteria Haematologica 2019 104 8 1682 1688 10.3324/haematol.2018.198549 30733264 83. Biernat MM Urbaniak-Kujda D Dybko J Kapelko-Słowik K Prajs I Wróbel T Fecal microbiota transplantation in the treatment of intestinal steroid-resistant graft-versus-host disease: two case reports and a review of the literature J Int Med Res 2020 48 6 300060520925693 10.1177/0300060520925693 32527171 84. Qi X Li X Zhao Y Wu X Chen F Ma X Treating steroid refractory intestinal acute graft-vs.-host disease with fecal microbiota transplantation: a pilot study Front Immunol. 2018 9 2195 10.3389/fimmu.2018.02195 30319644 85. Biagi E Zama D Rampelli S Turroni S Brigidi P Consolandi C Early gut microbiota signature of aGvHD in children given allogeneic hematopoietic cell transplantation for hematological disorders BMC Med Genomics 2019 12 1 49 10.1186/s12920-019-0494-7 30845942 86. Ramai D Zakhia K Ofosu A Ofori E Reddy M Fecal microbiota transplantation: donor relation, fresh or frozen, delivery methods, cost-effectiveness Ann Gastroenterol 2019 32 1 30 38 30598589 87. Jiang ZD Jenq RR Ajami NJ Petrosino JF Alexander AA Ke S Safety and preliminary efficacy of orally administered lyophilized fecal microbiota product compared with frozen product given by enema for recurrent Clostridium difficile infection: a randomized clinical trial PLoS ONE 2018 13 11 e0205064 10.1371/journal.pone.0205064 30388112 88. Wardill HR Secombe KR Bryant RV Hazenberg MD Costello SP Adjunctive fecal microbiota transplantation in supportive oncology: emerging indications and considerations in immunocompromised patients EBioMedicine 2019 44 730 740 10.1016/j.ebiom.2019.03.070 30940601 89. Doki N Suyama M Sasajima S Ota J Igarashi A Mimura I Clinical impact of pre-transplant gut microbial diversity on outcomes of allogeneic hematopoietic stem cell transplantation Ann Hematol 2017 96 9 1517 1523 10.1007/s00277-017-3069-8 28733895 90. Gupta S Allen-Vercoe E Petrof EO Fecal microbiota transplantation: in perspective Therap Adv Gastroenterol 2016 9 2 229 239 10.1177/1756283X15607414 26929784 91. Kelly CR Kahn S Kashyap P Laine L Rubin D Atreja A Update on Fecal Microbiota Transplantation 2015: indications, methodologies, mechanisms, and outlook Gastroenterology 2015 149 1 223 237 10.1053/j.gastro.2015.05.008 25982290 92. van Bekkum DW Roodenburg J Heidt PJ van der Waaij D Mitigation of secondary disease of allogeneic mouse radiation chimeras by modification of the intestinal microflora J Natl Cancer Inst 1974 52 2 401 404 10.1093/jnci/52.2.401 4150164 93. Navari RM Buckner CD Clift RA Storb R Sanders JE Stewart P Prophylaxis of infection in patients with aplastic anemia receiving allogeneic marrow transplants Am J Med 1984 76 4 564 572 10.1016/0002-9343(84)90274-2 6424464 94. Vossen JM Heidt PJ van den Berg H Gerritsen EJ Hermans J Dooren LJ Prevention of infection and graft-versus-host disease by suppression of intestinal microflora in children treated with allogeneic bone marrow transplantation Eur J Clin Microbiol Infect Dis 1990 9 1 14 23 10.1007/BF01969527 2105890 95. Bekker V Zwittink RD Knetsch CW Sanders I Berghuis D Heidt PJ Dynamics of the gut microbiota in children receiving selective or total gut decontamination treatment during hematopoietic stem cell transplantation Biol Blood Marrow Transplant 2019 25 6 1164 1171 10.1016/j.bbmt.2019.01.037 30731251 96. Ponziani FR Zocco MA D'Aversa F Pompili M Gasbarrini A Eubiotic properties of rifaximin: disruption of the traditional concepts in gut microbiota modulation World J Gastroenterol 2017 23 25 4491 4499 10.3748/wjg.v23.i25.4491 28740337 97. Lopetuso LR Petito V Scaldaferri F Gasbarrini A Gut microbiota modulation and mucosal immunity: focus on rifaximin Mini Rev Med Chem 2015 16 3 179 185 10.2174/138955751603151126121633 26643042 98. Townsend CM Parker CE MacDonald JK Nguyen TM Jairath V Feagan BG Antibiotics for induction and maintenance of remission in Crohn's disease Cochrane Database Syst Rev. 2019 2 2 cd012730 30731030 99. Weber D Oefner PJ Dettmer K Hiergeist A Koestler J Gessner A Rifaximin preserves intestinal microbiota balance in patients undergoing allogeneic stem cell transplantation Bone Marrow Transplant 2016 51 8 1087 1092 10.1038/bmt.2016.66 26999466 100. Shono Y Docampo MD Peled JU Perobelli SM Velardi E Tsai JJ Increased GVHD-related mortality with broad-spectrum antibiotic use after allogeneic hematopoietic stem cell transplantation in human patients and mice Sci Transl Med. 2016 8 339 339ra71 10.1126/scitranslmed.aaf2311 27194729 101. Kumari R Palaniyandi S Hildebrandt GC Microbiome: an emerging new frontier in graft-versus-host disease Dig Dis Sci 2019 64 3 669 677 10.1007/s10620-018-5369-9 30523482 102. Farowski F Bücker V Vehreschild JJ Biehl L Cruz-Aguilar R Scheid C Impact of choice, timing, sequence and combination of broad-spectrum antibiotics on the outcome of allogeneic haematopoietic stem cell transplantation Bone Marrow Transplant 2018 53 1 52 57 10.1038/bmt.2017.203 29131156 103. Nishi K Kanda J Hishizawa M Kitano T Kondo T Yamashita K Impact of the use and type of antibiotics on acute graft-versus-host disease Biol Blood Marrow Transplant 2018 24 11 2178 2183 10.1016/j.bbmt.2018.06.031 30417828 104. Tanaka JS Young RR Heston SM Jenkins K Spees LP Sung AD Anaerobic antibiotics and the risk of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation Biol Blood Marrow Transplant. 2020 26 2053 2060 10.1016/j.bbmt.2020.07.011 32682948 105. Gavriilaki M Sakellari I Anagnostopoulos A Gavriilaki E The impact of antibiotic-mediated modification of the intestinal microbiome on outcomes of allogeneic hematopoietic cell transplantation: systematic review and meta-analysis Biol Blood Marrow Transplant 2020 26 9 1738 1746 10.1016/j.bbmt.2020.05.011 32447043